Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia Treated With Ex Vivo Gene Therapy
2024-513905-29-00Phase 3Authorised
- Sponsor
- bluebird bio
- Start
- Sep 2024
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of betibeglogene autotemcel in beta thalassemia, sponsored by bluebird bio. Planned start Sep 2024; status: authorised.
02
Drugs
betibeglogene autotemcel
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2024-513905-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513905-29-00.